GSK1265744 30mg + Placebo + GSK1265744 5mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infection, Human Immunodeficiency Virus
Conditions
Infection, Human Immunodeficiency Virus
Trial Timeline
Jun 9, 2009 → Aug 13, 2009
NCT ID
NCT00920426About GSK1265744 30mg + Placebo + GSK1265744 5mg
GSK1265744 30mg + Placebo + GSK1265744 5mg is a phase 2 stage product being developed by Shionogi for Infection, Human Immunodeficiency Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT00920426. Target conditions include Infection, Human Immunodeficiency Virus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00920426 | Phase 2 | Completed |
Competing Products
20 competing products in Infection, Human Immunodeficiency Virus